FSSAI files three cases against Nestlé India over infant nutrition products
FSSAI has initiated three adjudication cases against Nestlé India, citing promotional claims on NAN Excella Pro Stage 1 and Lactogen Pro 1, along with alleged non-conforming biotin levels in a follow-up formula.
What happened
FSSAI filed three adjudication cases against Nestle India over promotional claims on NAN Excella Pro Stage 1 and Lactogen Pro 1, plus non-conforming biotin
Key facts
- Three infant nutrition products
- Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020
- Section 3 of the Infant Milk Substitutes Act, 1992
- Three separate adjudication cases
- Nestle India shares down nearly 2% to ₹1,345.45 at 1310 hours
Why this matters
Any partnership, acquisition or portfolio review involving infant nutrition should apply heightened regulatory diligence to claims substantiation, nutrient specifications and India-specific compliance systems.
What to watch
- FSSAI adjudication notices, hearing dates, penalties, directions to alter labels or promotions, and any recall or stop-sale order.
- Additional FSSAI sampling results involving Nestlé products, other infant-formula brands, or other micronutrient specifications.
- Nestlé India disclosures on provisions, product withdrawals, relabelling, sales impact or regulatory correspondence.
- Changes in pharmacy, hospital, pediatrician and e-commerce availability of the named products.
- Media coverage, parent-group reaction and social-media sentiment that could convert a compliance case into a trust issue.
- Any revision or stricter enforcement guidance on infant milk substitute marketing, health claims or nutrient tolerances.
- Conduct SKU-level audit of infant nutrition labels, digital content, medical-channel materials and retailer promotional copy.
- Increase batch testing and supplier verification for biotin and other regulated micronutrients; document corrective-action controls.
- Prepare a regulator-facing remediation plan and consumer communications emphasizing product safety, compliance and pediatric guidance.
- Review inventory exposure and contingency plans for affected Stage 1 and follow-up formula products, including relabelling or withdrawal scenarios.
- Monitor competitor claims and prepare for category-wide compliance changes that could alter promotional economics.